Azra AI has entered into a partnership with RevealDx to integrate that company's RevealAI-Lung lung nodule characterization software into Azra AI's enterprise incidental findings and oncology workflow platform.
The partnership builds on Azra AI's recent acquisition of Thynk Health, which offers cancer screening and incidental findings management. The incorporation of RevealAI-Lung into Azra AI's platform will help clinicians identify and manage high-risk nodules and access oncology workflow automation, according to the two firms.
RevealAI-Lung, which recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA), characterizes incidental lung nodules by generating a Malignancy Similarity Index score intended to help radiologists make more informed follow-up recommendations, RevealDx said. The software has been validated on over 1,500 patients, according to the firm.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
